ERBB2 (HER2) and MET are both well‐established oncogenes that drive tumor growth, survival, and therapy resistance (Arteaga and Engelman 2014; Hsu and Hung 2016; Mo and Liu 2017; Mo et al. 2022; Rubin et al. 2024). The gene discussed is MET; the disease is neoplasm.